Two short courses of Lemtrada prevented multiple sclerosis from becoming active and progressing for five years, a study reported.
Lemtrada’s maker, Sanofi-Genzyme, said the study covered the two-year CARE-MS ... Read more
A five-year study demonstrated that Sanofi-Genzyme’s Lemtrada (alemtuzumab) provides long-term benefits for relapsing-remitting multiple sclerosis patients, reducing relapse rates and preventing the progression of the disease. Importantly, ... Read more
A five-year study comparing the efficacy of different treatments for relapsing-remitting multiple sclerosis (RRMS) found that, in general, Lemtrada (alemtuzumab) and Tysabri (natalizumab) are more effective as therapies than ... Read more
Oral therapy Tecfidera (dimethyl fumarate) seems to be emerging as a first-line treatment for relapsing multiple sclerosis – according to Biogen, the company that developed it. ... Read more
Pin It on Pinterest